
conferenceseries.com

2nd World Congress on

Bio Summit & Molecular Biology Expo

October 10-12, 2016 Dubai, UAE



Feasibility of investing time and money in genetic engineering: Commercial's perspective

As we previously stated in our first speech, the emerging technologies (e.g., CRISPR-Cas9) provided an opportunity to every scientist with innovative view to achieve his goal with minimal money and time. To get an overview about the importance of genetic research, 2 examples will be discussed in details in this regard; the highest cited article in NATURE is a genetic study entitled "An integrated encyclopedia of DNA elements in the human genome" that has more than 4200 citations in the past 4 years. The other example is what professors Gerngross and Hutchinson achieved in the years 2000 to 2006; they genetically modified the yeast *Pichia pastoris* to produce functional erythropoietin. In 2006, Merck offered 400 million in cash to buy their innovative invention and keep them on the head of their project but huge funding. With the emerging technologies that ease the genetic engineering, it is worth to think of an investment in this field, there are many similar examples where simple lab with few innovative scientists turned into "money factory".

Biography

Saif Aldeen Saleh Al Ryalat is a leading Researcher in several aspects of medicine, including genetic engineering and neurology. He is working on a project to design a bio-production system to design aglycosylated antibodies that can replace monoclonal glycosylated antibodies that are used in several neurological diseases (relatively high cost). He is also a peer Reviewer for several journals and a Researcher with several high impact publications. He is currently working at School of Medicine at The University of Jordan where he had several honors and certificates.

saifryalat@yahoo.com